PFA Delivered with a Difference
Argá Medtech Completes Enrollment of Paroxysmal AF Cohort in the COHERENT-AF Pivotal IDE Study
The challenge
Despite advancements in cardiac ablation technology, long-term success remains underwhelming, between 40%–80% depending on number of procedures and the patient population. [Ganesan AN et al. Long-term outcomes of catheter ablation of atrial fibrillation: A systematic review and meta-analysis. JAHA 2013]
Radiofrequency (RF) and Cryothermy (Cryo) are the most used ablation energy sources to treat AFib, atrial flutter and all other heart arrhythmias.
- RF and Cryo are thermal energy sources using heat or cold, respectively, to destroy heart tissue responsible for the arrhythmia.
- Thermal energy delivery can be difficult to control, indiscriminately destroying tissue and increasing the risk of collateral injuries, such as esophageal fistulas, pulmonary vein stenosis, and phrenic nerve palsy. [Reddy V et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med 2023;DOI:10.1056/NEJMoa2307291]
Patients require a treatment option that is safer, faster and more effective. It requires a solution that can improve long-term outcomes.
Argá MEDTECH'S solution
Argá Medtech is developing a next generation, non-thermal, cardiac ablation system. Our unique Pulsed Field Ablation (PFA) System offers unmatched versatility when used with its proprietary catheter.
Please Note
Arga Medtech will not call, text, or email asking for
sensitive information without prior contact and
proper channels having been established.